News
-
California-based startup Mosanna Therapeutics, which raised $80 million last year for clinical development of MOS118 nasal spray for the treatment of obstructive sleep apnea, said that results from a Phase 1 study support progression into… Read more . . .
-
Tiziana Life Sciences has announced the initiation of the Phase 2a Healey ALS MyMatch BANYAN trial of intranasal foralumab in people with amyotrophic lateral sclerosis. The company announced in November 2024 the ALS Association would… Read more . . .
-
Kither Biotech has announced the initiation of a Phase 1b /2a study of KIT2014 inhaled PDE3/4 inhibitor in patients with COPD. The company recently announced results from a Phase 1 trial of KIT2014 in healthy… Read more . . .
-
Harro Höfliger says that dry-filling technology for metered dose inhaler production, which has previously been available only at laboratory scale, is now available for commercial scale production lines. Dry filling, which Harro has developed in… Read more . . .
-
Aptar Pharma has announced that its Orbital high-payload dry powder inhaler will be key to a Macquarie University research project titled “Unlocking the Potential of Dry Powder Carriers for Biologic Applications” which is funded by a… Read more . . .
-
AstraZeneca announced that the European Commission has approved the company’s Trixeo (Breztri) Aerosphere budesonide / glycopyrrolate / formoterol MDI for the treatment of asthma in patients aged 12 and older whose asthma is not adequately… Read more . . .
-
Chinese OINDP developer CF Pharmtech has announced the initiation of its Phase 1 trial of its ICF004 dry powder inhaler, which the company is developing for the treatment of fibrotic lung diseases. The study record… Read more . . .
-
Polyrizon has announced the initiation of its first clinical trial, a study of its Nasarix (PL-14) hydrogel nasal spray in patients with seasonal allergic rhinitis. In September 2025, the company said that it had submitted… Read more . . .
-
OINDP specialist CDMOs Bespak and Upperton have announced a new strategic collaboration that will offer Upperton nasal drug development services including formulation and clinical manufacturing capability, in conjunction with Bespak nasal delivery devices. Upperton introduced… Read more . . .
-
Insmed announced that the FDA has accepted the company’s sNDA to expand the use of Arikayce amikacin liposome inhalation suspension for the treatment of Mycobacterium avium complex (MAC) lung disease. Arikayce is delivered by PARI‘s Lamira nebulizer. According to… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here


